A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap

European Psychiatry

Volumn 30, Issue 6, 2015, Pages 728-735

  Schurhoff F ^a,b,c,d   Fond, G ^a,b,c,d   Berna, F ^d,e   Bulzacka, E ^a,b,c,d   Vilain, J ^a,b,c,d   Capdevielle, D ^d,f,g   Misdrahi, D ^d,h,i   Leboyer, M ^a,b,c,d   Llorca, P M ^d,j,k   Antoniol, B ^h,i   Vila, E ^h,i   Tessier, A ^h,i   Brunel, L ^a,b,c   Le Gloahec, T ^a,b,c   Zinetti Bertschy, A ^e   Vidailhet, P ^e   Danion, J M ^e   Offerlin Meyer, I ^e   Boulenger, J P ^f,g   Schandrin, A ^f,g   Yazbek, H ^f,g   Blanc, O ^j,k   Chereau Boudet, I ^j,k   Tronche, A M ^j,k   Lacelle, D ^j,k   Denizot, H ^j,k   Pires, S ^j,k   D'Amato, T ^l,m,n,o   Chesnoy Servanin, G ^l,m,n,o   Rey, R ^l,m,n,o   Vehier, A ^l,m,n,o   Dorey, J M ^l,m,n,o   Urbach, M ^p,q   Passerieux, C ^p,q   Hardy Bayle, M C ^p,q   Sebilleau, M ^p,q   Fonteneau, S ^p,q   Dubertret, C ^g,r   Le Strat, Y ^g,r   Portalier, C ^g,r   De Pradier, M ^g,r   Lancon C ^s,t   Faget, C ^s,t   Metairie, E ^s,t   Peri, P ^s,t   Vaillant, F ^s,t   Giraud Baro, E ^u   Delorme, C ^u   Fluttaz, C ^u   Roman, C ^u   Gabayet, F ^u   Dubreucq, J ^u   more..

^a INSERM U955   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d FONDATION FONDAMENTAL   (France)

^e HÔPITAL CIVIL   (France)

^f Montpellier 1 University   (France)

^g INSERM   (France)

^h CENTRE HOSPITALIER CHARLES PERRENS   (France)

ⁱ UMR 5287   (France)

^j UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^k UNIVERSITÉ CLERMONT AUVERGNE   (France)

^l UNIVERSITÉ DE LYON   (France)

^m UNIVERSITÉ LYON 1   (France)

ⁿ CENTRE HOSPITALIER LE VINATIER   (France)

^o HÔPITAL NEUROLOGIQUE   (France)

^p CENTRE HOSPITALIER DE VERSAILLES   (France)

^q CENTRE HOSPITALIER DE VERSAILLES   (France)

^r HÔPITAL LOUIS MOURIER   (France)

^s HÔPITAL SAINTE MARGUERITE   (France)

^t AIX MARSEILLE UNIVERSITY   (France)

^u CHS de Saint Egreve   (France)

more..

Author keywords

Expert centre; Guideline; Network; Schizophrenia; Translational research

Indexed keywords

ARTICLE; CLINICAL PRACTICE; FRANCE; HEALTH CARE DELIVERY; HUMAN; INTERNET; MENTAL HEALTH SERVICE; NEUROPSYCHOLOGICAL TEST; PATIENT CARE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHIZOPHRENIA; TRANSLATIONAL RESEARCH; EXPERT WITNESS; INTERDISCIPLINARY COMMUNICATION; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; PROCEDURES;

EXPERT TESTIMONY; FRANCE; HUMANS; INTERDISCIPLINARY COMMUNICATION; MODELS, ORGANIZATIONAL; PATIENT CARE MANAGEMENT; SCHIZOPHRENIA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84941025095     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2015.05.004     Document Type: Article

References (73)

1. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992, 6(3):201-208.
2. Altamura A.C., Serati M., Albano A., Paoli R.A., Glick I.D., Dell'Osso B. An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. Eur Arch Psychiatry Clin Neurosci 2011, 261:489-508.
3. Amador X.F.S.D. The scale to assess unawareness of mental disorder 1990, Columbia University and New York Psychiatric Institute, New York.
4. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Publishing, Arlington, VA. 5th ed.
5. Auquier P., Simeoni M.C., Sapin C., Reine G., Aghababian V., Cramer J., et al. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophr Res 2003, 63(1-2):137-149.
6. Baddeley A., Emslie H., Nimmo-Smith I. Doors and people 1994, Harcourt Assessment, Oxford.
7. Bauer M.S., Biswas K., Kilbourne A.M. Enhancing multiyear guideline concordance for bipolar disorder through collaborative care. Am J Psychiatry 2009, 166:1244-1250.
8. Bazin N., Brunet-Gouet E., Bourdet C., Kayser N., Falissard B., Hardy-Baylé M.C., et al. Quantitative assessment of attribution of intentions to others in schizophrenia using an ecological video-based task: a comparison with manic and depressed patients. Psychiatry Res 2009, 167(1):28-35.
9. Birchwood M., Smith J., Drury V., Healy J., Macmillan F., Slade M. A self-report insight scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand 1994, 89(1):62-67.
10. Brown S., Mitchell C. Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort. Soc Psychiatry Psychiatr Epidemiol 2012, 47:843-847.
11. Buss A.H., Perry M.P. The aggression questionnaire. J Pers Soc Psychol 1992, 63:452-459.
12. Caci H.M., Bouchez J., Bayle F.J. An aid for diagnosing attention-deficit/hyperactivity disorder at adulthood: psychometric properties of the French versions of two Wender Utah Rating Scales (WURS-25 and WURS-K). Compr Psychiatry 2010, 51(3):325-331.
13. Cardebat D., Doyon B., Puel M., Goulet P., Joanette Y. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 1990, 90:207-217.
14. Collins P.Y., Patel V., Joestl S.S., March D., Insel T.R., Daar A.S., et al. Grand challenges in global mental health. Nature 2011, 475:27-30.
15. Delis D.C., Kramer J.H., Kaplan E., Ober B.A. California verbal learning test 2000, The Psychological Corporation, San Antonio, TX, [Adult Version]. 2nd ed.
16. Demetrovics Z., Szeredi B., Rozsa S. The three-factor model of Internet addiction: the development of the Problematic Internet Use Questionnaire. Behav Res Methods 2008, 40(2):563-574.
17. Evans J.D., Heaton R.K., Paulsen J.S., Palmer B.W., Patterson T., Jeste D.V. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenic patients. Biol Psychiatry 2003, 53:422-430.
18. Favrod J., Zimmermann G., Raffard S., Pomini V., Khazaal Y. The Beck Cognitive Insight Scale in outpatients with psychotic disorders: further evidence from a French-speaking sample. Can J Psychiatry 2008, 53(11):783-787.
19. First S.R., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders, patient edition (SCID-P), version 2 1995, New York State Psychiatric Institute, Biometrics Research, New York.
20. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 2012, 153:321-330.
21. Green M.F., Hellemann G., Horan W.P., Lee J., Wynn J.K. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry 2012, 69:1216-1224.
22. Haro J.M., Ayuso-Mateos J.L., Bitter I., Demotes-Mainard J., Leboyer M., Lewis S.W., et al. ROAMER: roadmap for mental health research in Europe. Int J Methods Psychiatr Res 2014, 23(Suppl. 1):1-14.
23. Harvey P.D. Clinical applications of neuropsychological assessment. Dialogues Clin Neurosci 2012, 14:91-99.
24. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., et al. World Fderation of Scieties of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012, 13:318-378.
25. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013, 14:2-44.
26. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom Test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991, 86(9):1119-1127.
27. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
28. Henry C., Etain B., Mathieu F., Raust A., Vibert J.F., Scott J., et al. A French network of bipolar expert centres: a model to close the gap between evidence-based medicine and routine practice. J Affect Disord 2011, 131:358-363.
29. Hill M., Crumlish N., Clarke M., Whitty P., Owens E., Renwick L., et al. Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12years. Schizophr Res 2012, 141:215-221.
30. Kern L.A.D. French adaptation of the Problematic Internet Use Questionnaire. Evol Psychiatr 2012, 10.1016/j.evopsy.2012.07.002.
31. Lancon C., Reine G., Llorca P.M., Auquier P. Validity and reliability of the French-language version of the Positive and Negative Syndrome Scale (PANSS). Acta Psychiatr Scand 1999, 100(3):237-243.
32. Larsen T.K., McGlashan T.H., Johannessen J.O., Friis S., Guldberg C., Haahr U., et al. Shortened duration of untreated first episode of psychosis: changes in patient characteristics at treatment. Am J Psychiatry 2001, 158:1917-1919.
33. Lejoyeux M., Gorwood P., Stalla-Bourdillon A., Ades J. [Translation and application of the Simpson and Angus Scale of extrapyramidal symptoms]. Encephale 1993, 19(1):17-21.
34. Lesieur H.R., Blume S.B. The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 1987, 144(9):1184-1188.
35. Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Salanti G., et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012, 379:2063-2071.
36. Lipkovich I.A., Deberdt W., Csernansky J.G., Sabbe B., Keefe R.S., Kollack-Walker S. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24weeks of antipsychotic drug therapy. BMC Psychiatry 2009, 14:9-44.
37. Lloyd-Evans B., Crosby M., Stockton S., Pilling S., Hobbs L., Hinton M., et al. Initiatives to shorten duration of untreated psychosis: systematic review. Br J Psychiatry 2011, 198:256-263.
38. Malla A.K., Norman R.M., Manchanda R., Ahmed M.R., Scholten D., Harricharan R., et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res 2002, 54:231-242.
39. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005, 62:975-983.
40. McGlashan T.H. The profiles of clinical deterioration in schizophrenia. J Psychiatr Res 1998, 32:133-141.
41. McGorry P., Keshavan M., Goldstone S., Amminger P., Allott K., Berk M., et al. Biomarkers and clinical staging in psychiatry. World Psychiatry 2014, 13:211-223.
42. Meyers J.E., Zellinger M.M., Kockler T., Wagner M., Miller R.M. A validated seven-subtest short form for the WAIS-IV. Applied Neuropsychol 2013, 20(4):249-256.
43. Michie S., Pilling S., Garety P., Whitty P., Eccles M.P., et al. Difficulties implementing a mental health guideline: an exploratory investigation using psychological theory. Implementation Sci 2007, 26:2-8.
44. Misdrahi D., Verdoux H., Llorca P.M., Bayle F.J. [Therapeutic adherence and schizophrenia: the interest of the validation of the French translation of Medication Adherence Rating Scale (MARS)]. Encephale 2004, 30(4):409-410.
45. Mollard E., Cottraux J., Bouvard M. [French version of the Yale-Brown Obsessive Compulsive Scale]. Encephale 1989, 15(3):335-341.
46. National Institute for Health Clinical Excellence Psychosis and schizophrenia in adults: treatment and management. National Clinical Practice Guideline 82 2014, National Institute for Clinical Excellence, London.
47. Nelson H.E., O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex 1978, 14:234-244. [French adaptation: Mackinnon A, Mulligan R. Estimation de l'intelligence prémorbide chez les francophones. Encephale 2005;31:31-43].
48. Nordentoft M., Wahlbeck K., Hällgren J., Westman J., Osby U., Alinaghizadeh H., et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One 2013, 8(1):e55176.
49. Nuechterlein K.H., Green M.F. MCCB-MATRICS Consensus Cognitive Battery-Manual. Matrics Assessment Inc. (In MATRICS assessment battery with permission of Barbara Cornblatt, Biobehavioral Technologies, Inc.) 2006.
50. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychologia 1971, 9:97-113.
51. Ozomaro U., Wahlestedt C., Nemeroff C.B. Personalized medicine in psychiatry: problems and promises. BMC Med 2013, 11:132.
52. Palmer B.A., Pankratz V.S., Bostwick J.M. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005, 62:247-253.
53. Paquette D., Laporte L., Bigras M., Zoccolillo M. [Validation of the French version of the CTQ and prevalence of the history of maltreatment]. Sante Ment Que 2004, 29(1):201-220.
54. Patterson T.L., Goldman S., McKibbin C.L., Hughs T., Jeste D.V. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 2001, 27:235-245.
55. Pedrelli P., McQuaid J.R., Granholm E., Patterson T.L., McClure F., Beck A.T., et al. Measuring cognitive insight in middle-aged and older patients with psychotic disorders. Schizophr Res 2004, 71(2-3):297-305.
56. Prieto L., Sacristan J.A., Hormaechea J.A., Casado A., Badia X., Gomez J.C. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2004, 20(6):827-835.
57. Raffard S., Trouillet R., Capdevielle D., Gely-Nargeot M.C., Bayard S., Laroi F., et al. [French adaptation and validation of the scale to assess unawareness of mental disorder]. Can J Psychiatry 2010, 55(8):523-531.
58. Reitan R.M. The relation of the Trail Making Test to organic brain damage. J Consult Psychol 1955, 19:393-394.
59. Reitan R.M. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958, 8:271-276.
60. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999, 56:241-247.
61. Rummel-Kluge C., Kissling W. Psychoeducation in schizophrenia: new developments and approaches in the field. Curr Opin Psychiatry 2008, 21:168-172.
62. Ryan J.J., Ward L.C. Validity, reliability, and standard errors of measurement for two seven-subtest short forms of the Wechsler Adult Intelligence Scale-III. Psychol Assess 1999, 11(2):207-211.
63. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007, 64:1123-1131.
64. Salvatore P., Baldessarini R.J., Tohen M., Khalsa H.M., Sanchez-Toledo J.P., Zarate C.A., et al. McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry 2011, 72:183-193.
65. Shallice T., Burgess P.W. Deficits un strategy application following frontal lobe damage in man. Brain 1991, 114:727-741. [Adaptation used: Garnier C, Enot-Joyeux F, Jokic C, Le Thiec F, Desgranges B, Eustache F. Une évaluation des fonctions exécutives chez les traumatisés crâniens: l'adaptation du test des six éléments. Rev Neuropsychol 1998;8(3):385-414].
66. Startup M., Jackson M.C., Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol 2002, 41(Pt 4):417-422.
67. Stip E., Caron J., Renaud S., Pampoulova T., Lecomte Y. Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia. Compr Psychiatry 2003, 44(4):331-340.
68. Swift R.H., Harrigan E.P., Cappelleri J.C., Kramer D., Chandler L.P. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res 2002, 36(2):87-95.
69. Wechsler D. WAIS-III: administration and scoring manual 1997, Pearson, San Antonio, TX.
70. Wechsler D. WAIS-IV administration and scoring manual 2008, Pearson, San Antonio, TX.
71. Whitty P.F., Owoeye O., Waddington J.L. Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr Bull 2009, 35(2):415-424.
72. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
73. Zimmermann P., Fimm B. Testbatterie zur Aufmerksamkeitsprufung (TAP), Version 2.3. Handbuch 2010, Psytest, Wurselen.